Copay Accumulators: Pending CMS Reg May Offer More Clarity After Judge Limits Scope

Programs only allowed for brands with generic competition under court ruling, but related programs such as copay maximizers and so-called ‘alternative funding’ programs are not directly impacted by the decision.

Decision Goes A Long Way Toward Curtailing Practice, Patient Groups Say • Source: Shutterstock

After a federal court vacated the Centers for Medicare and Medicaid Services rule that allows commercial insurers and pharmacy benefit managers to broadly implement copay accumulator programs, stakeholders are looking to possible modifications of a pending rule for clarification of how payers may be able to use the mechanism.

Copay accumulator programs are used by commercial insurance plans to prevent manufacturer assistance from being counted

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

More from Pink Sheet

Pink Sheet Podcast: A New Director For US FDA’s Biologics Center, Guidance Production Slowdowns

 

Pink Sheet editors discuss the appointment of Vinay Prasad as the new director of the Center for Biologics Evaluation and Research and revelations that FDA layoffs now are hindering development of guidance documents.

US FDA Restoring Some Library Resources

 

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals, and laid off librarians have not been reinstated.

Recent and Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.